Opexa Therapeutics (Acer)
Company Details
Status: Public
Employees: 11-50
Location:
The Woodlands, Texas, United States
Type:
sample
Technology:
sample
sample
sample
About: Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.
Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Opexa Therapeutics (Acer) | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.